| GE Healthcare AG - Visipaque 270 mg/mL, Injektionslösung |
| 52228 | | 02 | | Visipaque 270 mg/mL | | Injektionslösung | | V08AB09 | | Iodixanol | | 15.04.1994 | | |
|
| Composition |
| iodixanolum 550 mg corresp. iodum 270 mg, trometamolum, natrii calcii edetas, calcii chloridum dihydricum, natrii chloridum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 0.76 mg. |
| Packungsbestandteile |
| Solution injectable | | | | | | | | Principe actif | Concentr. |
|---|
| Iodixanol | 550 mg/ml correspond Iod 270 mg/ml |
| | BAG: Principe actif | Concentr. |
|---|
| Iodixanol | 550 mg |
| | | | Agents auxilliaires |
|---|
| Acidum Hydrochloridum | | Calcium Chlorure | | Sodium Calcium Edetate | | Sodium Chlorure | | Trometamol |
| |
|
|
